10:27 AM EST, 01/09/2025 (MT Newswires) -- Exelixis ( EXEL ) said Thursday it has been notified by the US Food and Drug Administration that its supplemental new drug application for cabozantinib will no longer be discussed at an oncologic drugs advisory committee meeting.

The supplemental new drug application covers expanded approval of cabozantinib for adults with previously treated advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic.

The FDA will continue to consider the application with a Prescription Drug User Fee Act action date of April 3, the company said.

Price: 34.50, Change: +0.29, Percent Change: +0.85